华熙生物副总裁邹松岩答21：加速布局韩国医美与生物制造

Group 1 - The core viewpoint is that Huaxi Bio sees the South Korean market as a crucial area for international expansion, particularly in the rapidly growing medical aesthetics industry [2] - The China-Korea Business Forum highlighted discussions on manufacturing innovation, supply chain cooperation, and new consumer markets, with over 400 attendees from both countries [2] - Biomanufacturing is identified as a strategic high ground in the global technological revolution, with the "14th Five-Year Plan" emphasizing the need for forward-looking layouts in biomanufacturing and other future industries [2] Group 2 - Huaxi Bio, established in 2000 and listed on the STAR Market in 2019, specializes in the research and production of bioactive materials, holding a 44% share in the global hyaluronic acid raw material market and 70% in the domestic market [3] - The company entered the South Korean market in 2002 and has expanded into pharmaceuticals, medical aesthetics, cosmetics, and functional foods, with a new subsidiary established in Seoul in 2023 [3] - In the pharmaceutical sector, Huaxi Bio collaborates with top Korean companies in eye drops and joint injection products, while in medical aesthetics, its products cover over 90% of local production companies [3]